FGL1 and cancer: Recently, it was reported that FGL1 is highly expressed in several types of human cancer (e.g., lung cancer, prostate cancer, melanoma, gastric cancer, etc.)and is associated with resistance to programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1)-blockage therapy and poor prognosis of cancer patients (15, 16).